Masimo Co. (NASDAQ:MASI) Director Craig B. Reynolds Sells 2,053 Shares of Stock

Masimo Co. (NASDAQ:MASI) Director Craig B. Reynolds sold 2,053 shares of the business’s stock in a transaction on Friday, March 14th. The shares were sold at an average price of $166.13, for a total transaction of $341,064.89. Following the transaction, the director now owns 16,581 shares in the company, valued at $2,754,601.53. This trade represents a 11.02 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Masimo Stock Up 1.5 %

MASI stock opened at $168.21 on Friday. The company has a current ratio of 2.01, a quick ratio of 1.11 and a debt-to-equity ratio of 0.50. Masimo Co. has a twelve month low of $101.61 and a twelve month high of $194.88. The company’s 50 day moving average is $174.84 and its two-hundred day moving average is $157.36. The stock has a market cap of $9.07 billion, a P/E ratio of 116.01 and a beta of 1.03.

Masimo (NASDAQ:MASI) last announced its earnings results on Tuesday, February 25th. The medical equipment provider reported $1.80 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.42 by $0.38. The business had revenue of $600.70 million for the quarter, compared to analyst estimates of $593.35 million. Masimo had a net margin of 3.85% and a return on equity of 14.98%. Research analysts expect that Masimo Co. will post 4.1 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Masimo

Several institutional investors have recently made changes to their positions in the stock. FMR LLC raised its stake in Masimo by 41.2% in the 3rd quarter. FMR LLC now owns 6,756,618 shares of the medical equipment provider’s stock valued at $900,860,000 after purchasing an additional 1,970,883 shares during the last quarter. Capital Research Global Investors grew its holdings in shares of Masimo by 80.5% during the 4th quarter. Capital Research Global Investors now owns 2,454,975 shares of the medical equipment provider’s stock worth $405,807,000 after purchasing an additional 1,094,647 shares during the period. Massachusetts Financial Services Co. MA boosted its holdings in Masimo by 119.0% in the 4th quarter. Massachusetts Financial Services Co. MA now owns 1,735,167 shares of the medical equipment provider’s stock worth $286,823,000 after acquiring an additional 943,001 shares during the period. Alliancebernstein L.P. raised its position in shares of Masimo by 1,276.9% in the 4th quarter. Alliancebernstein L.P. now owns 947,391 shares of the medical equipment provider’s stock valued at $156,604,000 after purchasing an additional 878,587 shares in the last quarter. Finally, Corient Private Wealth LLC raised its position in shares of Masimo by 8,847.1% in the 4th quarter. Corient Private Wealth LLC now owns 347,683 shares of the medical equipment provider’s stock valued at $57,472,000 after purchasing an additional 343,797 shares in the last quarter. 85.96% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research firms recently weighed in on MASI. Needham & Company LLC reaffirmed a “hold” rating on shares of Masimo in a research note on Wednesday, February 26th. Stifel Nicolaus reaffirmed a “buy” rating and set a $190.00 price objective (up previously from $170.00) on shares of Masimo in a research note on Friday, November 22nd. Raymond James raised their price objective on shares of Masimo from $170.00 to $194.00 and gave the stock an “outperform” rating in a research note on Friday, December 27th. Wells Fargo & Company raised their price objective on shares of Masimo from $193.00 to $205.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 26th. Finally, Piper Sandler lifted their price target on shares of Masimo from $210.00 to $215.00 and gave the company an “overweight” rating in a research note on Wednesday, February 26th. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $194.80.

Masimo Company Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.